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It has to be remembered that the predictive value of raised ferritin levels is helpful only if ferritin levels are greater than 4000 mg/mL, because levels below this may accompany many common inflammatory febrile diseases. We also feel that an extremely high serum ferritin level in addition to classification criteria makes it much easier to diagnose AOSD. We could not get glycosylated ferritin levels done in our cases because they were not available.
Both patients initially responded to pulse therapy with high-dose methylprednisolone. However, anakinra or other immunosuppressive treatment and MAS/hemophagocytic lymphohistiocytosis-specific therapy including etoposide were not given or considered because both patients died within 2 days of pulse steroid therapy.
Delay in diagnosis, pleuritis, interstitial pneumonia, elevated ferritin levels, and failure of fever to subside after 3 days of treatment (prednisolone) are unfavorable prognostic factors for patients presenting with severe systemic form of AOSD. The poor outcome in our patients and many others in the literature can hopefully be improved by early recognition and diagnosis of AOSD. This is important because it can lead clinicians to initiate therapy early with corticosteroids. In all the reported cases, as well as in our cases, patients were initially managed with antibiotics and other supportive therapy for severe sepsis and multiorgan dysfunction syndrome. Although both patients initially responded to methylprednisolone, they probably died of severe inflammation (MAS). Because no autopsy was done, we cannot comment on the most probable cause of death in these cases.
CONCLUSIONS
(1) Adult-onset Still disease is a disease that needs prompt intervention because sometimes it may rapidly worsen with life-threatening events. It should be considered when a patient is not responding to antimicrobial therapy and other clinically compatible manifestations of AOSD are present, including spiking fevers and high ferritin levels. Early recognition of AOSD can lead to prompt initiation of appropriate therapy with decrease in morbidity and mortality in severe form of the disease.
(2) We also advocate that ferritin level may be an important diagnostic tool in the diagnosis of AOSD and therefore should be included in the classification criteria. 
A Development and Feasibility Study of a Peer Support Telephone Program in Rheumatoid Arthritis
To the Editor:
T he aim of this study was to describe the development and feasibility of a telephone peer support program that provides education and emotional support and enhances coping skills among rheumatoid arthritis (RA) patients. In an academic arthritis center, peer coaches received 5 training modules: (1) definition and expectations of peer coaching, (2) structure/management of phone calls, (3) confidentiality, (4) psychological techniques for encounters, and (5) referral guidelines and resources. Follow-up, acceptability, and comparison with patients . Participants reported many benefits from peer support. They felt less alone, 13 (62%); felt more part of a sharing community, 12 (57%); and had a better understanding of RA, 9 (43%). They felt calmer, 9 (43%); less sad, 5 (24%); and that they had more support from family and friends, 5 (24%). An RA telephone peer support program is feasible and acceptable to patients. Although the study was underpowered to detect statistical improvements, patients reported benefits suggesting the need for randomized evaluation. Many patients with RA can develop progressive disability, work loss, and premature mortality 1, 2 ; their pervasive symptoms can influence mood and role functioning. 1, 3 Research has shown that individuals with chronic illness usually require social support to achieve the best physical and emotional outcomes. 4, 5 Riemsma et al 6 demonstrated an inverse association between fatigue and lower self efficacy and problematic peer support in RA. The purpose of this study was to assess a telephone peer support program's feasibility, acceptability, and value among RA patients.
METHODS

Program Development and Peer Coach Training
The rationale for the program arose from an RA patient advisory group run at the R. B. Brigham Arthritis Center where members reported that their top concerns were feeling isolated and scared when first diagnosed. Peer coaches were recruited from the advisory group or were recommended by their rheumatologist. They attended 2 training sessions with the social worker (N.F.S.) that included 5 training modules: (1) definition and expectations of peer coaching, (2) structure/management of phone calls, (3) confidentiality, (4) psychological techniques for encounters, and (5) referral guidelines and support resources (Table 1) . A peer-coaching manual (Appendix 1, http://links.lww.com/RHU/A84) and training materials (Appendix 2, http://links.lww.com/ RHU/A85) that included (1) the first call sheet, (2) common questions with suggested answers, (3) the structure of the phone call, (4) visualization exercises, and (5) a roleplay handout were created. All participants were consented and then filled out a questionnaire, to help ascertain the best match for a coach. For the pilot analysis, peer support patients were matched with RA patients receiving standard care based on age, sex, and disease duration (±5 years). This study had approval from Patients and peer coaches were encouraged to speak with each other approximately once a week by phone for 6 months or as needed. Peer coaches tracked their topics and could call into the social worker at any time for support. There was also a regularly scheduled 60-minute group call setup every few months.
Measures and Analysis
Follow-up, acceptability, and comparison with patients receiving standard care included adjusted mean change differences at 6 months in fatigue, pain, self-efficacy, 7 function (SF-12, 5-question Mental Health Inventory), 8, 9 flare frequency, and medication adherence (ASK-20). 10 Baseline comparisons were made with χ 2 or t test. We ran postprogram analyses with and without the least-squares-mean method from the GLM procedure to adjust for baseline variable differences (SAS 9.4; SAS Institute Inc, Cary, NC). As a development and feasibility study (25 patients/group), this study was not powered as a randomized trial. Rather, our goal was to observe broader trends.
RESULTS
The study ran from Patients specifically indicated they wanted to discuss stress on marriage, caring for young children, and starting a new family.
talkers. Eighteen peer coaches had on average 1.7 (SD, 1.4) patients. The most common topics requested were how to manage flares, 10 (48%), medical aspects of RA, 10 (48%), and understanding how to live with RA, 9 (43%) ( Table 2) .
Peer Support Outcomes and Benefits
The peer support and standard care groups had similar demographics but worse baseline outcome variables. The Figure 1 indicates the magnitude and directionality of change adjusting for baseline group differences. The largest trends in improvement were the SF- Patients in the peer support program reported many benefits (Table 3) : 62% noted feeling less alone, 43% had a better understanding of their illness, and 57% felt part of an RA community. They also reported feeling calmer (43%), less sad (24%), and more support from their family and friends (24%) and that they maintained a healthier lifestyle (24%). Both the peer coaches and the patients remarked on how much the relationship benefited them.
DISCUSSION
In this study, we report on the development and feasibility of a telephone peer support program for RA patients. The evaluation indicated that peer support is a feasible and acceptable method of education and support. The patients reported benefits, including a better understanding of their illness, improved coping mechanisms, and feeling less isolated and calmer. After 6 months of peer support, the pilot analysis suggested trends toward benefits; however, the study was neither powered nor randomized to assess efficacy.
Research has shown that individuals with chronic illness usually require social support to achieve the best physical and emotional outcomes. 4, 5 Peer support systems matching patients with similar needs have been successful in addiction programs, sleep apnea, oncology treatment, mammography screening, and in promoting other physical and behavioral health outcomes.
11-14 A Cochrane review of 7 trials of peer support telephone health programs showed some evidence of efficacy, but none of these trials included arthritis patients. 15 To our knowledge, this is the first study to report on the development, feasibility, and potential value of a telephone peer support program for RA patients.
There are several limitations to our study. Our study was not a randomized controlled trial, so no conclusions about efficacy could be drawn. In addition, with 20 to 25 patients per group, there was limited ability to detect anything other than a large (0.8) effect. Although study participation was high, enrollment occurred only after rheumatologist referral and training, resulting in a relatively slow recruitment. Other suggestions for improvement can be found in Table 4 .
In summary, results from this preliminary study suggest that telephone peer support for RA patients is feasible and acceptable. The patients reported a variety of health and emotional benefits from the program. Peer coaches also found the program enjoyable. Data from the study suggest further development of the program and a randomized controlled design. D espite significant advances based on various combinations of conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and biologic DMARDs for the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA), remission and low disease activity rates are still approximately only 20% to 40%, and patients continue to face uncontrolled symptoms, progressive joint damage, and decreasing function. Although it is well known that combination therapy is superior to monotherapy in moderate to severe RA and PsA, waning drug efficacy often makes it challenging to achieve disease remission. Unfortunately, the use of 2 biologics together often increases the incidence of toxicity more than increasing efficacy. [1] [2] [3] As a highly targeted DMARD for RA, there is rationale for using tofacitinib, a Janus kinase inhibitor, in conjunction with a biologic as one would in combination therapy with other DMARDs such as methotrexate. Tofacitinib has multiple mechanisms of action, including interleukin 6, interleukin 8, monocyte chemotactic protein 1, and matrix metalloproteinases 2 (MMP2), MMP3, and MMP9, among others, and, thus, it is reasonable to combine it with other biologics. 4 In addition, tofacitinib was efficacious in a 16-week randomized, placebo-controlled trial in spondyloarthropathy and in randomized, placebo-controlled trials in psoriasis. 5, 6 Tofacitinib is currently not US Food and Drug Administration (FDA) approved for use with biologics because of concerns for potential increases in toxicity. As a DMARD (not a biologic) and like methotrexate, one would have to consider potential adverse effects such as liver, hematologic, and infection problems and, in the case of tofacitinib, hyperlipidemia.
To our knowledge, there are no data looking at the combination of tofacitinib with biologic therapy. Our goal in this small case series was to examine preliminary data for the safety of combination therapy with tofacitinib and rituximab, etanercept, or tocilizumab.
MATERIALS AND METHODS
Clinical data from 5 RA patients and 1 PsA patient were extracted from a single practice (D.E.F.). Data were extracted from the charts-concomitantly for disease activity and safety or retrospectively for historical data. Data were obtained from prior to starting tofacitinib/biologic combination therapy until completion of 4 to 28 months of combination treatment. Data extracted included patient demographics, disease characteristics, significant comorbidities, previous and concomitant medications, adverse events (AEs) and serious adverse events (SAEs), laboratory data, and Clinical Disease Activity Index (CDAI).
Descriptive statistics included means and ranges. Serious and nonserious AEs were defined using FDA criteria. 7 After consultation with the local institutional review board, no ethics board approval was required in accordance with the policy of our institution because this was an anonymized, small case series, and data extraction required no contact with patients.
RESULTS
Three RA patients were on tofacitinib in combination with tocilizumab, one with rituximab and one with etanercept. The PsA patient was on tofacitinib and tocilizumab. The RA patients fulfilled the 1987 American College of Rheumatology classification, and the PsA patient fulfilled the CASPAR (ClASsification criteria for Psoriatic ARthritis). 8, 9 
